NOVAVAX INC Business Operations Contracts & Agreements
34 Contracts & Agreements
- Collaboration Agreements (5 contracts)
- Development Agreements (3)
- Sales Agreements (12)
- Services Agreements (5)
- Settlement Agreements (3)
- Supply Agreements (5)
- Termination Agreements (1)
- Confidential Settlement Agreement and Release, dated March 21, 2024, between the Company and FUJIFILM Diosynth Biotechnologies UK Limited, FUJIFILM Diosynth Biotechnologies Texas,... (Filed With SEC on May 10, 2024)
- Termination and Settlement Agreement, dated as of February 16, 2024, between the Company and Gavi Alliance (Filed With SEC on February 28, 2024)
- Settlement Agreement and General Release, dated August 8, 2023, between the Company and SK bioscience Co., Ltd (Filed With SEC on November 9, 2023)
- At Market Issuance Sales Agreement by and among Novavax, Inc., Jefferies LLC and B. Riley Securities, Inc., dated August 8, 2023 (Filed With SEC on August 8, 2023)
- Settlement Agreement, dated September 30, 2022, between the Company and FUJIFILM Diosynth Biotechnologies UK Limited, FUJIFILM Diosynth Biotechnologies Texas, LLC, and FUJIFILM... (Filed With SEC on November 9, 2022)
- Letter of Amendment to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of September 26, 2022, between the Company and The Secretary of State for Business,... (Filed With SEC on November 9, 2022)
- Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of July 1, 2022, between the Company and The Secretary of State for Business, Energy, and Industrial Strategy,... (Filed With SEC on November 9, 2022)
- Statement of Work No. 1 to the Contract Development Manufacture Agreement (Filed With SEC on August 9, 2022)
- Amendment No. 1 to the Contract Development Manufacture Agreement (Filed With SEC on August 9, 2022)
- Contract Development Manufacture Agreement (Filed With SEC on August 9, 2022)
- Change Order No. 1 to the Collaboration and Exclusive License Agreement between Novavax, Inc. and SK Bioscience Company Limited, dated as of March 31, 2022 (Filed With SEC on May 10, 2022)
- Statement of Work No. 1 to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021 (Filed With SEC on March 1, 2022)
- Amendment to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021 (Filed With SEC on March 1, 2022)
- Supply Agreement between the Company, Serum Institute of India Private Limited and Serum Life Sciences Limited, executed as of October 26, 2021 (Filed With SEC on March 1, 2022)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley Securities, Inc., dated June 15, 2021 (Filed With SEC on June 15, 2021)
- Collaboration and Exclusive License Agreement between Novavax, Inc. and Takeda Pharmaceutical Company Limited, dated as of February 24, 2021 (Filed With SEC on May 10, 2021)
- Collaboration and Exclusive License Agreement between Novavax, Inc. and SK Bioscience Company Limited, dated as of February 12, 2021 (Filed With SEC on May 10, 2021)
- SARS-CoV-2 Vaccine Supply Agreement, effective as of October 22, 2020, between Novavax, Inc. and The Secretary of State for Business, Energy and Industrial Strategy, acting on... (Filed With SEC on March 1, 2021)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley Securities, Inc., dated January 22, 2021 (Filed With SEC on January 22, 2021)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley Securities, Inc., dated November 10, 2020 (Filed With SEC on November 10, 2020)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated May 18, 2020 (Filed With SEC on May 18, 2020)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated March 2, 2020 (Filed With SEC on March 2, 2020)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated January 21, 2020 (Filed With SEC on January 21, 2020)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated December 31, 2018 (Filed With SEC on December 31, 2018)
- At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated December 29, 2017 (Filed With SEC on December 29, 2017)
- AMENDMENT No 5 to MASTER SERVICES AGREEMENT (Filed With SEC on February 27, 2015)
- AMENDMENT No 4 to MASTER SERVICES AGREEMENT (Filed With SEC on March 12, 2014)
- AMENDMENT No 3 to MASTER SERVICES AGREEMENT (Filed With SEC on October 30, 2013)
- AMENDMENT No 2 to MASTER SERVICES AGREEMENT (Filed With SEC on March 12, 2013)
- EXHIBIT1.1 At MarketIssuance Sales Agreement (Filed With SEC on October 2, 2012)
- AMENDMENT No 1 to MASTER SERVICES AGREEMENT (Filed With SEC on November 8, 2011)
- At Market Issuance Sales Agreement (Filed With SEC on September 15, 2009)
- At Market Issuance Sales Agreement (Filed With SEC on January 13, 2009)
- SUPPLY AGREEMENT (Filed With SEC on August 14, 2006)
